Oral Fluoropyrimidines in Cancer Treatment

References

• Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903
   PubMed Web of Science ®Google Scholar
• Sotos G A, Allegra C J. Biochemical modulation of cancer chemotherapy. Principles of Antineoplastic Drug Development and Pharmacology, R L Schilsky, G Milano, M J Ratain. Marcel Dekker, New York 1996; 143–187
   Google Scholar
• Meta-analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537–3541
   PubMed Web of Science ®Google Scholar
• Liu G, Fraussen E, Fitch M I, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–115
   PubMed Web of Science ®Google Scholar
• Grem J L. 5-Fluoropyrimidines. Cancer Chemotherapy and Biotherapy: Principles and Practice, B A Chabner, D L Longo. Lippincott-Raven, Philadelphia 1996; 149–211
   Google Scholar
• Heggie G D, Sommadossi J P, Cross D S, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203–2206
   PubMed Web of Science ®Google Scholar
• Etienne M C, Cheradame S, Fischel J L, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663–1670
   PubMed Web of Science ®Google Scholar
• Spector T, Cao S, Rustum Y M, et al. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 1995; 55: 1239–1241
   PubMed Web of Science ®Google Scholar
• Davis S T, Joyner S S, Baccanari D P, et al. 5-Ethynyluracü (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem Pharm 1994; 48: 233–236
   PubMed Web of Science ®Google Scholar
• Leichman C G, Fleming T R, Muggia F M, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. J Clin Oncol 1995; 13: 1303–1311
   PubMed Web of Science ®Google Scholar
• Hansen R M, Ryan L, Anderson T, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996; 88: 668–674
   PubMed Web of Science ®Google Scholar
• Sobrero A F, Aschele C, Bertino J R. Fluorouracil in colorectal cancer—a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15: 368–381
   PubMed Web of Science ®Google Scholar
• Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–308
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, an oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharm 1998; 55: 1091–1097
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxiflurimidine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities on tumors in human cancer xenografts. Cancer Res 1998; 58: 685–690
   PubMed Web of Science ®Google Scholar
• Schuller J, Cassidy J, Reigner B, et al. Tumor selectivity of Xeloda in colorectal cancer patients. Proc Am Soc Clin Oncol 1997; 16: 227, (abstract)
   Google Scholar
• Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and or metastatic cancer. J Clin Oncol 1998; 16: 2977–2985
   PubMed Web of Science ®Google Scholar
• Budman D R, Meropol N J, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998; 16: 1795–1802
   PubMed Web of Science ®Google Scholar
• Cassidy J, Dirix L, Bissett D, et al. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998; 4: 2755–2761
   PubMed Web of Science ®Google Scholar
• Blum J L, Jones S E, Buzdar A U, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485–493
   PubMed Web of Science ®Google Scholar
• Blum J L, Budzar A U, Dieras V, et al. A multicenter phase II trial of Xeloda(tm) (capecitabine) in taxane-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 107a, (abstract)
   Google Scholar
• O'Reilly S M, Moiseyenko V, Talbot D C, et al. A randomized phase II study of Xeloda (capecitabine) vs. paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc Am Soc Clin Oncol 1998; 17: 163a, (abstract)
   Google Scholar
• O'Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase II study of Xeloda (capecitabine) vs. CMF as first-line chemotherapy of breast cancer in women aged > 55 years. Proc Am Soc Clin Oncol 1998; 17: 103a, (abstract)
   Google Scholar
• Findlay M, Van Cutsem E, Kocha W, et al. A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 227a, (abstract)
   Google Scholar
• Cox J V, Pazdur R, Thibault A, et al. A phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 265a, (abstract)
   Google Scholar
• Twelves C, Harper P, Van Cutsem E, et al. A phase III trial (SO14796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 263a, (abstract)
   Google Scholar
• Khoury P, Villalona-Calero M, Blum J, et al. Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer. Proc Am Soc Clin Oncol 1998; 17: 206a, (abstract)
   Google Scholar
• Taguchi T. Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation of 5-FU. Oncology 1997; 54: 12–18
   PubMed Web of Science ®Google Scholar
• Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1998; 22: 333–338
   Google Scholar
• Friedman M A. A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). Cancer Treat Rev 1980; 7: 205–213
   PubMed Web of Science ®Google Scholar
• Muggia F M, Wu X, Spicer D, et al. Phase I and pharmacokinetic study of oral UFT, a combination of 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res 1996; 2: 1461–1467
   PubMed Web of Science ®Google Scholar
• Rustum Y M, Cao S, Creaven P J, et al. Phase I clinical trials and pharmacokinetics of uracil-ftorafur combination (UFT) and leucovorin (LV) in patients with advanced colorectal cancer. Ther Res 1993; 14: 241–249
   Google Scholar
• Pazdur R, Lassere Y, Diaz-Canton E, et al. Phase I trials of uraciltegafur (UFT) using 5-and 28-day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs 1996; 7: 728–733
   PubMed Web of Science ®Google Scholar
• Spicer D, Muggia F, Tulpule A, et al. Phase I circadian dosing of daily oral uracil (U) plus 1-(tetrahydro-2-furany1)-5-fluorouracil (FT) with leucovorin (LV). Proc Am Assoc Can Res 1991; 10: 342
   Google Scholar
• Gonzalez-Baron M, Feliu J, Ordonez A., et al. Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal. Anticancer Res 1993; 13: 759–762
   PubMed Web of Science ®Google Scholar
• Pazdur R, Lassere Y, Diaz-Canton E, et al. Phase I trial of uraciltegafur (UFT) plus oral leucovorin: 14 day schedule. Invest New Drags 1997; 15: 123–128
   PubMed Web of Science ®Google Scholar
• Saltz L B, Leichman C G, Young C W, et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low-dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995; 75: 782–785
   PubMed Web of Science ®Google Scholar
• Meropol N J, Rustum Y M, Petrelli N J, et al. A phase I and pharmacokinetic study of oral uracil. ftorafur and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 1996; 37: 581–586
   PubMed Web of Science ®Google Scholar
• Pazdur R., Lassere Y., Diaz-Canton E, et al. Phase I trial of uraciltegafur (UFT) plus oral leucovorin:28 day schedule. Cancer Invest 1998; 16: 145–151
   PubMed Web of Science ®Google Scholar
• Ho D H, Pazdur R, Covington W, et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 1998; 4: 2085–2088
   PubMed Web of Science ®Google Scholar
• Malik S TA, Talbot D, Clarke P I, et al. Phase II trial of UFT in advanced colorectal and gastric cancer. Br 3 Cancer 1990; 62: 1023–1025
   PubMed Web of Science ®Google Scholar
• Sanchiz F, Milla A. Tegafur UFT in advanced colorectal cancer; a phase II study. Anticancer Res 1988; 5: 1122
   Google Scholar
• Gonzalez Baron M, Feliu J., de la Gandara I, et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 1995; 31 A: 2215–2219
   Google Scholar
• Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of colorectal cancer. J Clin Oncol 1994; 12: 2296–2300
   PubMed Web of Science ®Google Scholar
• Meropol N J, Sonnichsen D S, Birkhofer M. J., et al. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemother Pharmacol 1999; 43: 221–226
   PubMed Web of Science ®Google Scholar
• Pazdur R, Patt Y, Ajani J, et al. Phase II/pharmacology study of UFT (BMS-200604) and leucovorin in refractory colorectal cancer patients. Proc Am Soc Clin Oncol 1997; 16: 270, (abstract)
   Google Scholar
• Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of ORZEL (oral uracil-tegafur (UFT) plus leucovorin (LV)) vs parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 527, (abstract)
   Google Scholar
• Pazdur R, Douillard J-Y, Skillings J R, et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 263a, (abstract)
   Google Scholar
• Kim Y H, Shin S W, Kim B S, et al. A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. Oncology 1997; 11: 119–123
   PubMedGoogle Scholar
• Kurihara M, Izumi T, Yoshida S, et al. A cooperative randomized study of tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 1991; 82: 613–620
   PubMedGoogle Scholar
• Sasagawa T, Hoy N., Endo T., et al. Randomized controlled trial of MMC + UFT and MMC + 5-FU therapy in advanced gastric cancer. Gan To Kagaku Ryoho 1994; 21: 1179–1185
   PubMedGoogle Scholar
• Sato A, Hasegawa K, Kurihara M., et al. Combination chemotherapy with tegafur-uracil (UFT) and cisplatin (CDDP) for advanced gastric cancer. Jpn J Cancer Chemother 1995; 22: 1355–1362
   PubMedGoogle Scholar
• Feliu J, Gonzales Baron M., Garcia-Giron C., et al. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A Phase II Study of the ONCOPAZ Cooperative Group. Cancer 1996; 78: 211–216
   PubMed Web of Science ®Google Scholar
• Arima S, Aohsato K, Hisatstigu T, et al. Multicentre randomized study of adjuvant chemotherapy with mitomycin C and tegafur-uracil in gastric cancer. Eur J Surg 1994; 160: 227–232
   PubMedGoogle Scholar
• Tanaka J, Inuyama Y, Fujii M, et al. Clinical trials on UFT in the treatment of head and neck cancer. Auris Nasus Larynx 1995; 12: S261–S266
   Google Scholar
• Gonzalez-Larriba J L, Carbonero I., Valera G. JS., et al. Neoadjuvant therapy with cisplatin/fluorouracil versus cisplatin/UFT in locally advanced squamous cell head and neck cancer. Oncology 1997; 11: 90–97
   PubMedGoogle Scholar
• Valverde Gonzalez J. J., Dominguez S., et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil versus cisplatin and ftorafur-uracil (UFT) in advanced squamous head and neck cancer. Proc Am Assoc Clin Oncol 1993; 12: 281, (abstract)
   Google Scholar
• Daniels M, Diaz-Rubio E, Guillem V, et al. Phase II trial of UFT activity in pretreated breast cancer patients. Jpn J Clin Oncol 1993; 23: 363–365
   PubMed Web of Science ®Google Scholar
• Villalon A., De H., Gulman L, Samson M C, et al. A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at the Phillipjnes General Hospital. Oncology 1997; 54: 2–6
   PubMed Web of Science ®Google Scholar
• Klaaussen U, Lang S, Borquez D, et al. Oral UFT/LV in combination with paclitaxel in the second-line treatment of patients with metastatic breast cancer: results of a phase I/II trial. Proc Am Assoc Clin Oncol 1999; 18: 107a, (abstract)
   Google Scholar
• Iglesias L, Torrija Codes E.M., et al. UFT in combination as adjuvant therapy in breast cancer. Oncology 1997; 11: 74–81
   PubMedGoogle Scholar
• Ichinose Y, Yano T., Kudoh S., et al. A phase II trial. UFT plus cisplatin in advanced non-small cell lung cancer: interim analysis of 67 patients. Oncology 1997; 11: 103–105
   PubMedGoogle Scholar
• Shimizu N, Teramoto S, Hitomi S, et al. A randomized controlled post-operative adjuvant chemotherapy trial of MMC + tegafur and MMC + UFT for adenocarcinoma of the lung—first study. Jpn J Lung Cancer 1991; 31: 1011–1019
   Google Scholar
• Wada J, Hitomi S., Teramatsu T., et al. Adjuvant chemotherapy after complete resection in non-small cell lung cancer. J Clin Oncol 1996; 14: 1048–1054
   PubMed Web of Science ®Google Scholar
• Cao S, Rustum Y., Spector M. T. 5-Ethynyluracil (776C86): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994; 54: 1507–1510
   PubMed Web of Science ®Google Scholar
• Baker S D, Khor S., Adjei P. AA., et al. Pharmacokinetics, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85. an inactivator of DPD. J Clin Oncol 1996; 14: 3085–3096
   PubMed Web of Science ®Google Scholar
• Humerickhouse R A, Dolan M., Haraf E. DJ., et al. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res 1999; 5: 291–298
   PubMed Web of Science ®Google Scholar
• Grem J, Harold N, Bi D, et al. A phase I and pharmacologic (PK/PD) study of weekly oral fluorouracil (Fura) given with eniluracil (GW 776C85) and leucovorin in patients with solid tumors. Proc Am Assoc Clin Oncol 1999; 18: 173a, (abstract)
   Google Scholar
• Schilsky R L, Hohneker J, Ratain M J, et al. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 1998; 16: 1450–1457
   PubMed Web of Science ®Google Scholar
• Baker S D, Diasio R, Lucas V S, et al. Phase I and pharmacologic study of oral 5FU on a chronic 28 day schedule in combination with the DPD inactivator 776C85. Proc Am Assoc Clin Oncol 1996; 15: 486, (abstract)
   Google Scholar
• Goldberg R M, Kugler J, Sargent D J, et al. A phase in trial of a seven-day regimen of oral 776C85 plus a 5-day regimen of oral 5-fluorouracil (5-FU) in untreated patients with metastatic colorectal cancer: a NCCTG study. Proc Am Assoc Clin Oncol 1998; 17: 282a, (abstract)
   Google Scholar
• Mani S, Beck T, Chevlen E, et al. A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer. Proc Am Assoc Clin Oncol 1998; 17: 281a, (abstract)
   Google Scholar
• Schilsky R, Mani S, Meropol N, et al. Clinical evaluation of eniluracil plus 5-fluorouracil in colorectal cancer. Program Proceeds: Chemotherapeutic Strategies for Treatment of Colorectal Cancer. European Cancer Centre, Amsterdam 1999
   Google Scholar
• Burris H A, Ravdin P, Gutheil J, et al. Eniluracil/5-FU in anthracycline and taxane-refractory breast cancer. Proc Am Assoc Clin Oncol 1999; 18: 107a, (abstract)
   Google Scholar
• Smith I, Johnston S, O'Brien M, et al. High activity with eniluracil (776C85) and continous low dose oral 5-fluorouracil (1 mg/m2 for 2 daily) as first line chemotherapy in patients with advanced breast cancer: a phase II study. Proc Am Assoc Clin Oncol 1999; 18: 106a, (abstract)
   Google Scholar
• Benson A B, Mitchell E, Abramson N, et al. A multicenter phase II trial of oral eniluracil plus 5-FU in patients with inoperable hepatocellular carcinoma. Proc Am Assoc Clin Oncol 1999; 18: 256a, (abstract)
   Google Scholar
• Shirasaka T, Shimamato Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004–4009
   PubMed Web of Science ®Google Scholar
• Cao S, Lu K, Toth K, et al. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. Clin Cancer Res 1999; 5: 267–274
   PubMed Web of Science ®Google Scholar
• Peters G J, Van Groeningen C J, Schomage J H, et al. Phase I clinical and pharmacokinetic study of S-l, an oral 5-fluorouracil (5-FU)-based antineoplastic agent. Proc Am Assoc Clin Oncol 1997; 16: 227a, (abstract)
   Google Scholar
• Hoff P M, Wenske C A, Medgyesy D C, et al. Phase I and pharmaacokinetic (PK) study of the novel oral fluoropyrimidine, S-l. Proc Am Assoc Clin Oncol 1999; 18: 173a, (abstract)
   Google Scholar
• Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anti-cancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34: 1715–1720
   PubMed Web of Science ®Google Scholar
• Kurihara M, Koizumi W, Hasegawa K, et al. Late phase 11 study of S-l, a novel oral fluoropyrimidine derivative in patients with advanced gastric cancer. Proc Am Assoc Clin Oncol 1998; 17: 262a, (abstract)
   Google Scholar
• Baba H, Ohtsu A, Sakata Y, et al. Late phase II study of S-l in patients with advanced colorectal cancer in Japan. Proc Am Assoc Clin Oncol 1998; 17: 277a, (abstract)
   Google Scholar